Commentary: RBE in proton therapy - where is the experimental in vivo data?
Commentary: RBE in proton therapy - where is the experimental in vivo data? Acta Oncol. 2019 Oct 03;:1-3 Authors: Sørensen BS PMID: 31578911 [PubMed - as supplied by publisher]
This article reviews the current indications and future directions of radiotherapy in lung cancer management. PMID: 31739938 [PubMed - in process]
This study presented a method of plan selection in IMPT to address the challenge of delivering treatment to the prostate and the pelvic lymph nodes, with different motion patterns. The plan library used different positions of the prostate created from a population model of day-to-day target motion. Plan selection from this library reduced the dose to the rectum and bladder without compromising target coverage compared to conventional static delivery.
PALO ALTO, Calif., Nov. 18, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the South Florida Proton Therapy Institute (SFPTI), a Proton International facility, on the campus of Delray Medical Center, has treated its first patient utilizing the Varian ProBeam® Compact single-room proton therapy system. Proton therapy can be used to treat many types of tumors including in the brain, head and neck, central nervous system and lung, and more precisely targets cancer cells...This story is related to the following:Radiotherapy Systems
Abstract Dose in proton radiotherapy is generally prescribed by scaling the physical proton dose by a constant value of 1.1. Relative biological effectiveness (RBE) is defined as the ratio of doses required by two radiation modalities to cause the same level of biological effect. The adoption of an RBE of 1.1. assumes that the biological efficacy of protons is similar to photons, allowing decades of clinical dose prescriptions from photon treatments and protocols to be utilized in proton therapy. There is, however, emerging experimental evidence that indicates that proton RBE varies based on technical, tissue and ...
CONCLUSIONS: This work demonstrate the clinical acceptability of substituting MR converted RSP images instead of CT for IMPT planning of prostate cancer. This further translates into higher contouring accuracy along with lesser imaging dose. PMID: 31734604 [PubMed - as supplied by publisher]
Conclusion Here, we present a case of HMSC with early and progressive distant metastasis. We aim to add to an understanding of the behavior of this entity. Although this neoplasm may typically be indolent, further classification of high-risk features is necessary to identify rare aggressive cases. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Abstract | open access Full text
The primary purpose of this study was to investigate the impact of an air gap (AG) on breast cancer plans that are generated using the intensity-modulated proton therapy technique.
Proton therapy ’s direct and precise application of radiation for mid-stage lung cancer is being investigated in an ongoing phase III trial at the University of Cincinnati.
CONCLUSION: In the presence of mediastinal involvement and absence of range shifters Raystation ADC may be clinically acceptable in lung IMPT. Otherwise, MC algorithm would be recommended to ensure accuracy of treatment plans. ADVANCES IN KNOWLEDGE: Although MC algorithm is more accurate compared to ADC in lung IMPT, ADC may be clinically acceptable where there is mediastinal involvement and absence of range shifters. PMID: 31696729 [PubMed - as supplied by publisher]
The Miami Cancer Institute on Thursday will begin using the innovative Tumor Treating Fields device for patients with malignant pleural mesothelioma. It is the first new treatment approved for mesothelioma by the U.S. Food and Drug Administration in more than 15 years. “This is actually pretty exciting for us,” Dr. Rupesh Kotecha, the radiation oncologist who will oversee the treatment protocol in Miami, told The Mesothelioma Center at Asbestos.com. “It’s another tool in our armamentarium. It’s something we can offer patients that has shown a real benefit.” The noninvasive Tumor Treating...